PDCD1 and cervical carcinoma: In the clinical trial KEYNOTE-58, pembrolizumab (programmed cell death-1(PD-1) monoclonal antibody) was used to treat advanced cervical cancer, and the overall response rate (ORR) was 12.2% [15].